Efficacy and Safety of Xacrel ® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
Conditions: Multiple Sclerosis; Relapsing-Remitting Interventions: Biological: Ocrelizumab (CinnaGen, Iran); Biological: Ocrelizumab (Roche, Switzerland) Sponsor: Cinnagen Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials